Representative 2-DE gel images of (A) gastric tumors and (B) non-neoplastic gastric samples.

<p>Proteins were resolved over the pI range 3–10, followed by 12.5% SDS-PAGE and stained with SYPRO® Ruby. The identified proteins that showed significantly altered expression in gastric carcinogenesis are labeled with the respective protein IDs.</p

Top canonical pathways by Ingenuity Pathways Analysis.

*<p>The p-value was calculated using the right-tailed Fisher's Exact Test. Threshold: p<0.05.</p

Top networks involved by Ingenuity Pathways Analysis.

<p>Top networks involved by Ingenuity Pathways Analysis.</p

The identified proteins were grouped into different classes.

<p>A) Enrichment of GeneGo disease using the differentially regulated proteins between neoplastic and matched non-neoplastic samples; B) Cellular compartments, C) Biological processes, D) Molecular functions and E) Chromosomal location of all identified proteins.</p

Clinicopathological characteristics of gastric cancer samples used for protein profiling analysis.

a<p><i>H. pylori</i> infection was also present in all corresponding non-neoplastic gastric samples.</p

Clinicopathological characteristics, ENO1 and HSPB1 expression in gastric cancer samples.

<p>RQ: relative quantification; T: tumor gastric samples; N: non-neoplastic gastric samples.</p

ENO1 expression in gastric samples.

<p>A) the ratio of the sum of spot #5506 and #6505 ENO1 expression between tumor and matched controls; B) the ratio of Spot #5506 ENO1 expression between tumor and matched controls; C) the ratio of spot #6505 ENO1 expression between tumor and matched controls; D) Western blot using anti-ENO1 and anti-ACTB antibodies; E) the ratio of ENO1 protein expression between tumor and matched controls by western blot analysis; F) Relative <i>ENO1</i> mRNA quantification – gastric tumor samples normalized by matched controls. T: tumor gastric sample; N: non-neoplastic gastric samples. *To calculate the ratio, 0 values (lack of a spot on the 2-DE gel) were replaced with 0.0001.</p

HSPB1 expression in gastric samples.

<p>A) the ratio of spot #4203 HSPB1 expression between tumor and matched controls; B) western blot using anti-HSPB1 and anti-ACTB antibodies; C) the ratio of HSPB1 protein expression between tumor and matched controls by western blot analysis; D) Relative HSPB1 mRNA quantification – gastric tumor samples normalized by matched controls. T: tumor gastric sample; N: non-neoplastic gastric samples.</p

Immunohistochemical analysis of PHB in gastric samples.

<p>A) PHB staining in normal gastric mucosa (400x); B) PHB immunoreactivity in normal gastric mucosa and inflammatory cells (400x); C) strong PHB staining in intestinal metaplastic cells (400x); D) strong PHB staining in an intestinal-type tumor; E) moderate to intense PHB immunoreactivity in a poorly differentiated tumor; F) moderate to intense PHB immunoreactivity in a moderately differentiated tumor; G) weak PHB staining in a moderately differentiated tumor (400x); D) weak PHB staining in a diffuse-type tumor (400x).</p

rs6917 allele-specific <i>PHB</i> expression.

<p>A) The log₁₀ of FAM/VIC intensity ratio for <i>PHB</i> plotted against the log₁₀ of FAM/VIC allele ratio of mixing homozygous DNAs at different ratios (8∶1, 4∶1, 2∶1, 1∶1, 1∶2, 1∶4, 1∶8 FAM/VIC allele). B) <i>PHB</i> expression by rs6917 genotype in gastric samples. C) C/T allelic ratio in cDNA from gastric samples of heterozygous patients by sequencing; D) FAM/VIC allelic ratio in gastric samples of heterozygous patients using a Custom Genotyping TaqMan assay, in which a specific probe for the C allele was labeled with FAM dye and a minor allele T probe was labeled with VIC dye. *Differentially expressed between groups by the T-test for independent samples, <i>P</i><0.05.</p